Relationship between menopausal hormone therapy and breast cancer: A nationwide population‐based cohort study
International Journal of Gynecology & Obstetrics · 2024
DOI: 10.1002/ijgo.15461 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift International Journal of Gynecology & Obstetrics, 2024. Verfasst von Jin-Sung Yuk. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, Sanggye Paik Hospital, School of Medicine, Inje University, Seoul, Republic of Korea. Hauptthemen laut MEDLINE: Breast Neoplasms, Estrogen Replacement Therapy, Progestins. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 32 Literaturangaben.
Abstract (Originalsprache)
Objective
To explore the risk of breast cancer associated with menopausal hormone therapy (MHT), including the various progestogens used today.
Methods
The study included postmenopausal women over 40 years from the National Health Insurance Database in South Korea (2011–2014) who either used MHT for over 6 months (MHT group) or never used MHT (non‐MHT group) and were matched 1:1 based on several variables using propensity score matching. Both groups were followed until 2020.
Results
The non‐MHT and MHT groups comprised 153 736 women each. In Cox proportional hazard analysis with time‐dependent covariates, MHT was associated with an increased risk of breast cancer (hazard ratio [HR] 1.22, 95% confidence interval [CI] 1.15–1.3). Tibolone, estradiol valerate (EV)/medroxyprogesterone acetate (MPA), EV/norethisterone acetate (NETA), conjugated equine estrogen (CEE), EV, estradiol hemihydrate (EH), CEE/micronized progesterone (MP), CEE/MPA, EV/MP, EV/MPA, and EH/MP did not increase the risk of breast cancer compared with the non‐MHT group. However, EH/drospirenone (DRSP) (HR 1.51, 95% CI 1.38–1.66), EH/NETA (HR 1.66, 95% CI 1.34–2.06), EH/dydrogesterone (DYD) (HR 1.37, 95% CI 1.12–1.68), and EV/cyproterone acetate (CPA) (HR 1.74, 95% CI 1.54–1.96) increased the risk of breast cancer compared with the non‐MHT group.
Conclusions
MHT was linked to increased breast cancer risk, but not all MHTs. Specific combined therapies (EH/DRSP, EH/DYD, EH/NETA, and EV/CPA) were associated with higher risk, whereas estrogen alone and tibolone were not.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Obstetrics and Gynecology, Sanggye Paik Hospital, School of Medicine, Inje University, Seoul, Republic of Korea.
ORCID-Profile: Jin-Sung Yuk
Zitieren
APA
Yuk, J. S. (2024). Relationship between menopausal hormone therapy and breast cancer: A nationwide population‐based cohort study. International Journal of Gynecology & Obstetrics. https://doi.org/10.1002/ijgo.15461
Vancouver
Yuk JS. Relationship between menopausal hormone therapy and breast cancer: A nationwide population‐based cohort study. International Journal of Gynecology & Obstetrics. 2024. doi:10.1002/ijgo.15461
BibTeX
@article{Yuk2024,
author = {Yuk, Jin-Sung},
title = {Relationship between menopausal hormone therapy and breast cancer: A nationwide population‐based cohort study},
journal = {International Journal of Gynecology & Obstetrics},
year = {2024},
doi = {10.1002/ijgo.15461}
}
EUVIMED